Core Viewpoint - Zhongguancun Bank has been fined a total of 1.4 million yuan for various regulatory violations, including improper deposit absorption practices and inadequate management of internet personal loans [1][2][3] Regulatory Violations - The bank was penalized for paying third-party companies to absorb deposits, which is a rare violation in the banking sector [1][2] - Previous violations include issues with internet loan management and compliance with regulatory standards, leading to fines of 1.3 million yuan in September 2023 and 500,000 yuan in August 2022 [3] Financial Performance - For the first half of 2025, Zhongguancun Bank reported revenues of 1.031 billion yuan and a net profit of 123 million yuan, reflecting year-on-year growth of 14.9% and 17.5% respectively [5] - As of the end of 2024, the bank's loan balance was 43.931 billion yuan, with self-operated loans accounting for 26.94% of the total [5] Business Model and Challenges - The bank's internet loan business heavily relies on third-party platforms for customer acquisition, which poses challenges to its own customer outreach capabilities [5] - The bank's commission expenses related to third-party collaborations reached 1.593 billion yuan by the end of 2024, marking a year-on-year increase of 28.36% [6] Shareholder Risks - The second-largest shareholder, Beijing Beishuiyuan Technology Co., Ltd., is currently a subject of enforcement actions, while the third-largest shareholder, Beijing Oriental Garden Environment Co., Ltd., is listed as a dishonest executor [6] Customer Complaints - In the past 30 days, there have been 166 complaints related to Zhongguancun Bank, with issues including high interest rates and aggressive debt collection practices [6]

北京海润天睿律师事务所 关于北京中关村科技发展（控股）股份有限公司 2025 年第六次临时股东会之 法律意见书 中国·北京 二〇二五年九月十六日 北京海润天睿律师事务所 关于北京中关村科技发展（控股）股份有限公司 2025 年第六次临时股东会之 法律意见书 致：北京中关村科技发展（控股）股份有限公司 北京海润天睿律师事务所（以下称"本所"）受北京中关村科技发展（控股） 股份有限公司（以下称"公司"）的委托，指派本所朱卫江、齐佳惠律师（以下称 "本所律师"）出席公司 2025 年第六次临时股东会（以下称"本次股东会"），根 据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公 司法》、《上市公司股东会规则》（以下称"《股东会规则》"）及《北京中关村 科技发展（控股）股份有限公司章程》（以下称"《公司章程》"）的规定，对本 次股东会召开的合法性进行见证，并出具法律意见书。 在本法律意见书中，根据《股东会规则》的要求，仅对公司本次股东会的召 集、召开程序是否符合法律、行政法规、《股东会规则》和《公司章程》的规定、 出席会议人员资格、召集人资格是否合法有效、会议的表决程序和表决结果是否 合法有效等 ...

2025 年第六次临时股东会决议公告 共 5 页 证券代码：000931 证券简称：中关村 公告编号：2025-110 北京中关村科技发展（控股）股份有限公司 2025 年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现否决提案的情形； 2、本次股东会涉及变更前次股东会决议的情形具体如下：本次股东会审议 通过的《关于取消公司为山东华素向恒丰银行申请融资授信提供担保的议案》， 将变更于 2025 年 3 月 21 日召开的 2025 年第三次临时股东会审议通过的《关于 公司和山东中关村为山东华素向恒丰银行申请 1,000 万元融资授信提供担保的议 案》； 3、公司于 2025 年 8 月 27 日披露《关于召开 2025 年第六次临时股东会的通 知》（公告编号：2025-099）。2025 年 9 月 5 日，公司收到控股股东国美控股集 团有限公司《关于北京中关村科技发展（控股）股份有限公司 2025 年第六次临 时股东会增加临时议案的提案函》，决定将经公司第九届董事会 2025 年度第五 次临时会议审 ...

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Shandong Huasu Health Care Products Co., Ltd., has obtained a utility model patent certificate from the National Intellectual Property Administration of China, which will enhance the company's intellectual property protection system and promote technological innovation [1][2]. Group 1 - The utility model patent is effective from the date of the announcement and has a validity period of ten years from the date of application [1]. - The newly acquired patent is not expected to have a significant impact on the company's recent production and operations, but it will contribute to the company's competitive advantage through improved intellectual property protection [1][3]. - The company emphasizes the importance of leveraging its independent intellectual property to foster a continuous innovation mechanism and enhance overall competitiveness [1].

Core Insights - The Tianjin government is actively promoting the integration of the Baodi District into the Beijing-Tianjin-Hebei collaborative development strategy, enhancing its significance in the region [1] Group 1: Industrial Development - The "Zhongguancun-like" industrial ecosystem is being established in the Beijing-Tianjin Zhongguancun Science City, with 1,883 market entities and sustained double-digit growth in key economic indicators [3] - The Science City has signed an agreement with the Zhongguancun Development Group to deepen cooperation, with an 80 million yuan investment planned for a new round of capital increase [3] - Baodi District has adopted a comprehensive service package from Zhongguancun, implementing 22 policy measures to support high-quality development in the Science City [3][4] Group 2: Innovation and Technology - The Science City has developed a full-chain incubation system, recognized as an innovative base for entrepreneurship by the China Association for Science and Technology [4] - Collaborations with prestigious universities have led to the appointment of "technology vice presidents" for ten companies, enhancing innovation capabilities [4] - Significant technological advancements have been achieved, with certifications for international and domestic leading levels in semiconductor and robotics technologies [4] Group 3: Transportation Infrastructure - The opening of the Jing-Tang and Jing-Bin intercity railways has marked Baodi's entry into the "high-speed rail era," significantly improving transportation connectivity [5] - Baodi has upgraded 170 kilometers of trunk roads and constructed 39 kilometers of new primary roads, resulting in a total road network of 2,235 kilometers [5] - The Baodi Station has become a hub for high-speed rail, with a 34.8% increase in daily train services and a doubling of average passenger volume since the initial opening [6]

Group 1: Company Overview - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. (referred to as "Zhongguancun") held an investor relations activity on September 15, where executives discussed the company's main business development and market trends with over ten institutional investors [1] - Zhongguancun's subsidiary, Duoduo Pharmaceutical Co., Ltd., won a centralized procurement bid for its Siberian Ginseng Injection, effective until December 31, 2027 [1] Group 2: Sales Performance and Market Strategy - The management indicated that sales revenue for Siberian Ginseng Injection is expected to grow by 38% year-on-year in the first half of 2025, although significant volume increases have not yet materialized due to delays in the procurement execution period [1] - The management expressed optimism that the product could achieve the goal of "volume through price" as the procurement process deepens and hospital development progresses [2] Group 3: Product Development - Zhongguancun's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., is developing two differentiated products for treating Attention Deficit Hyperactivity Disorder (ADHD), including a chewable sustained-release tablet and an oral sustained-release suspension [2] - These products are designed to improve medication adherence among children, particularly those with swallowing difficulties, offering more flexible dosing options compared to traditional sustained-release tablets [2] Group 4: New Market Ventures - Zhongguancun has made significant strides in the green building materials sector, successfully winning a bid for a wind power mixed tower project, marking its entry into the wind power market [3] - The company aims to establish a green production system focused on low energy consumption, low emissions, and high performance [4]

9月15日，北京中关村科技发展（控股）股份有限公司在北京市朝阳区霄云路26号鹏润大厦B座22层公 司会议室，以线上结合线下的形式，接受了天风证券、华安证券、首创证券等12家机构的特定对象调研 。公司董事兼总裁侯占军，独立董事史录文、毕克，以及多位副总裁等参与接待。 本次调研围绕公司多项业务展开，以下为主要内容： 1.刺五加注射液集采效果：2025年上半年，刺五加 注射液销售收入同比增长38%，毛利率同比增长18%。虽医疗端销量因集采执标期延后等原因未大幅增 加，但从长远看，凭借集采带来的市场准入优势及后续执标推进，未来有望实现"以价换量"。 2.哌甲酯 在研产品优势：北京华素制药股份有限公司两款哌甲酯在研产品（缓释咀嚼片、口服缓释干混悬剂）， 相比缓释片，具有适用人群更广、剂量调整灵活、提高儿童用药依从性等差异化优势。 3.经营性现金流 下滑原因：剔除上年同期145.8万元税收返还影响，公司经营性现金流仍大幅下滑。2025年H1应收账款 从年初9.56亿增至10.24亿 ，但并非因回款周期延长，主要是销售商品现金收入下降1.28%（盐酸贝尼地 平片部分省市集采未中标致收入缩减），以及购买商品现金支出上涨4.1 ...

Group 1 - Company Zhongguancun announced the acquisition of a utility model patent for a "toothpaste packaging box UV coding machine" by its subsidiary Shandong Huasu Health Care Products Co., Ltd. [1] - As of January to June 2025, Zhongguancun's revenue composition is as follows: 80.15% from biomedicine, 13.22% from concrete, 4.12% from elderly health, and 2.51% from other sectors [1] - The current market capitalization of Zhongguancun is 4 billion yuan [1]

Group 1 - The company Zhongguancun announced that its subsidiary Shandong Huasu Health Care Products Co., Ltd. has received a utility model patent certificate from the National Intellectual Property Administration [1] - The patent is for a "UV coding machine for toothpaste packaging" [1]

证券代码：000931 证券简称：中关村 公告编号：2025-109 关于下属公司山东华素健康护理品公司取得实用新型专利证书的公告 共 1 页 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素健康护理品公司取得实用新型 专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属 公司山东华素健康护理品有限公司取得国家知识产权局颁发的实用新型专利证 书，具体情况如下： 1、国家知识产权局颁发的实用新型专利证书。 特此公告 | 实用新型名称 | | 专利申请日 | | | | | 授权公告日 | | | 专利号 | | 授权公告号 | | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一种牙膏包装盒 | 2024 | 年 | 12 | 月 10 日 | 2025 | 年 | 09 月 | 12 日 | ZL | 2024 | 2 ...